AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05528315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06120374
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.
Trial: NCT06120374
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
Trial: NCT06305832
Drug: Androgen deprivation therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information
Trial: NCT06522100
Drug: Intravenous administration of Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take intravenous administration of Methylprednisolone (500mg/100ml by IV over 30 minutes per day) for 3 days.
Trial: NCT06522100
Drug: Perfusion of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take perfusion of placebo (G5%: 100ml over 30 minutes per day) for 3 days.
Trial: NCT04065672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
Trial: NCT05106400
Drug: ZTlido (Lidocaine Topical System) 1.8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Trial: NCT04814004
Drug: hCD19.IL15.CAR-iNKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
Trial: NCT06437041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Trial: NCT03594630
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive chemotherapy
Trial: NCT05505955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects took Placebo in Part 1 and Part 2.
Trial: NCT04539795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT05248919
Drug: Epclusa (nucleotide HCV NS5B polymerase inhibitors).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
Trial: NCT05425472
Drug: HR070803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR070803
Trial: NCT05461131
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antibiotic
Trial: NCT05744674
Drug: HR18034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR18034 228mg/342mg/456mg
Trial: NCT03896516
Drug: GLWL-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.
Trial: NCT05326490
Drug: PB-201 matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively
Trial: NCT05235269
Drug: I124-AT01 only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.
Trial: NCT05183360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06297642
Drug: TQB2928 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD47 monoclonal antibody
Trial: NCT06555549
Drug: DEH113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT06555549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT06182085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06654934
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 8 weeks, 5 mg/day for 4 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 2485 mg).
Trial: NCT06654934
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 14 weeks, 5 mg/day for 24 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 3605 mg).
Trial: NCT06594432
Drug: R-CHOP+Z+MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and MCD, BN2, and N1 subtypes will receive 5 cycles of R-CHOP combined with MTX + Zanubrutinib, followed by 1 cycle of R-MTX-Zanubrutinib.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles.
Trial: NCT06594432
Drug: R-CHOP+MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and EZB, A53, and other gene subtypes will receive 5 cycles of R-CHOP combined with MTX, followed by 1 cycle of R-MTX.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles.
Trial: NCT04806464
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
Trial: NCT06172309
Drug: NTQ1062
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet(s) PO
Trial: NCT06169059
Drug: JLP-2004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of JLP-2004(COX-2 inhibitor)
Trial: NCT04808661
Drug: Optimal medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (strictly control of their blood pressure and heart rate)
Trial: NCT05684211
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
Trial: NCT00279487
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00751517
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00751517
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06255431
Drug: Ezerra cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen.
Trial: NCT00002002
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05877508
Drug: AER002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of AER002
Trial: NCT05438303
Drug: AZD9833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
Trial: NCT05438303
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
Trial: NCT06273215
Drug: The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate,10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
Trial: NCT06649110
Drug: LTP
RxNorm normalized name: Saltpeter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTP001
Trial: NCT06649110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00040989
Drug: BAY 56-3722
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06329076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo tablets
Trial: NCT00002999
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05357651
Drug: LB1410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 and anti-TIM-3 bispecific antibody
Trial: NCT05024032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03550352
Drug: TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 6 capsules taken throughout the day by weeks 5-12 (15 mg THC/15 mg CBD total per day).
Trial: NCT03550352
Drug: TN-C200M2 oral capsules (CBD 200 mg)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will start by taking 1 capsule once daily for 1 week (200 mg CBD) and increase the number of capsules as tolerated to a maximum of 4 capsules taken throughout the day by weeks 5-12 (800 mg CBD total).
Trial: NCT05494164
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal corticosteroids in addition to nasal irrigation with sea water; for patients with allergy the standard treatment is oral antihistamines with or without oral corticosteroids.
Trial: NCT04801017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride injection
Trial: NCT04840823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06091826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections
Trial: NCT05478837
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05234697
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was used for maintenance of anesthesia.
Trial: NCT05330286
Drug: LMI070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT05330286
Drug: LMI070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT05330286
Drug: LMI070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution given in fasted state
Trial: NCT05330286
Drug: LMI070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution given in fed state
Trial: NCT06354439
Drug: Methotrexate Sodium
RxNorm normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg of methotrexate IM, single dose
Trial: NCT04674761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical in appearance to experimental drug (odevixibat).
Trial: NCT06354088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.
Trial: NCT04777175
Drug: immunity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient receives immunotherapy
Trial: NCT06595680
Drug: Medialipide 20% perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.
Trial: NCT06595680
Drug: NaCl 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.
Trial: NCT00280839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04922567
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m² iv on day1
Trial: NCT04922567
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m² iv on day 1
Trial: NCT06445062
Drug: RMC-6236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06445062
Drug: mFOLFOX6 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06445062
Drug: mFOLFIRINOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06445062
Drug: RMC-9805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06248749
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Iron supplement
Trial: NCT04866602
Drug: Atoguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
Trial: NCT06459427
Drug: Conservative non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
Trial: NCT05368012
Drug: MIDCAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
Trial: NCT03922048
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
Trial: NCT03922048
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose to be determined from Cohort 1.
Trial: NCT03922048
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose to be determined from Cohorts 1 and 2.
Trial: NCT03922048
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose to be determined from Cohort 1 Part A.
Trial: NCT05757544
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Placebo will be administered
Trial: NCT05679258
Drug: US-sourced DARZALEX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
Trial: NCT05679258
Drug: CN-sourced DARZALEX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
Trial: NCT05679258
Drug: EU-sourced DARZALEX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
Trial: NCT06003270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00760032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, one capsule per day during four weeks.
Trial: NCT04634253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05156034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV doses of placebo.
Trial: NCT05895812
Drug: Deuremidevir Hydrobromide Tablets
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JT001 single dose, 0.3g
Trial: NCT05366062
Drug: ERC1671
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).
Trial: NCT05366062
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.
Trial: NCT06413082
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
Trial: NCT06450990
Drug: BGY-1601-VT
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
Trial: NCT05865002
Drug: AUR107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT00823693
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05255458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
Trial: NCT05497453
Drug: Tyrosine kinase inhibitor One
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine Kinase Inhibitor